Role of runt-related transcription factor 2 in signal network of tumors as an inter-mediator

Cancer Letters

Volumn 361, Issue 1, 2015, Pages 1-7

  Sun, Shan Shan ^a   Zhang, Lun ^a   Yang, Jingxuan ^b   Zhou, Xuan ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Co factors; Oncogenesis; Osteolysis; RUNX2; Tumor

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 (2 AMINO 5 BENZOXAZOLYL) 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 4 AMINE; 3 (6 BROMO 2 PYRIDINYL) 2 CYANO N (1 PHENYLETHYL)ACRYLAMIDE; 4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; 4 AMINO N [1 (4 CHLOROPHENYL) 3 HYDROXYPROPYL] 1 (7H PYRROLO[2,3 D]PYRIMIDIN 4 YL) 4 PIPERIDINECARBOXAMIDE; ANTINEOPLASTIC AGENT; AZD 2014; AZD 8055; BINDING PROTEIN; CC 223; CISPLATIN; EVEROLIMUS; EXEMESTANE; FULVESTRANT; KSI 3716; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1 INHIBITOR; MYC PROTEIN INHIBITOR; PALOMID 529; PROTEIN INHIBITOR; SEPANTRONIUM BROMIDE; TRAMETINIB; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

BONE ATROPHY; BREAST CANCER; CARCINOGENESIS; CELL PROLIFERATION; COLORECTAL CANCER; ENHANCER REGION; EPITHELIAL MESENCHYMAL TRANSITION; GENE ACTIVATION; HUMAN; METASTASIS; MOLECULAR INTERACTION; NEOPLASM; OSSIFICATION; OSTEOBLAST; PHENOTYPE; POLYOMA VIRUS; PRIORITY JOURNAL; PROTEIN FUNCTION; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR CELL; ANIMAL; METABOLISM; PATHOLOGY;

POLYOMAVIRUS;

ANIMALS; CORE BINDING FACTOR ALPHA 1 SUBUNIT; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84925273532     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.02.042     Document Type: Review

References (67)

1. Komori T. Regulation of skeletal development by the Runx family of transcription factors. J. Cell. Biochem 2005, 95:445-453.
2. Komori T. Regulation of bone development and extracellular matrix protein genes by RUNX2. Cell Tissue Res 2010, 339:189-195.
3. Otto F., Thornell A.P., Crompton T., Denzel A., Gilmour K.C., Rosewell I.R., et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997, 89:765-771.
4. Li Q.L., Ito K., Sakakura C., Fukamachi H., Inoue K., Chi X.Z., et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002, 109:113-124.
5. Levanon D., Bettoun D., Harris-Cerruti C., Woolf E., Negreanu V., Eilam R., et al. The Runx3 transcription factor regulates development and survival of TrkC dorsal root ganglia neurons. EMBO J. 2002, 21:3454-3463.
6. Inoue K., Ozaki S., Shiga T., Ito K., Masuda T., Okado N., et al. Runx3 controls the axonal projection of proprioceptive dorsal root ganglion neurons. Nat. Neurosci 2002, 5:946-954.
7. Komori T. Runx2, a multifunctional transcription factor in skeletal development. J. Cell. Biochem 2005, 95:445-453.
8. Khalid O., Baniwal S.K., Purcell D.J., Leclerc N., Gabet Y., Stallcup M.R., et al. Modulation of Runx2 activity by estrogen receptor-α: implications for osteoporosis and breast cancer. J. Endocrinol 2008, 149:5984-5995.
9. Baniwal S.K., Khalid O., Sir D., Buchanan G., Coetzee G.A., Frenkel B. Repression of Runx2 by androgen receptor (AR) in osteoblasts and prostate cancer cells: AR binds Runx2 and abrogates its recruitment to DNA. Mol. Endocrinol 2009, 23:1203-1214.
10. Kuo Y.H., Zaidi S.K., Gornostaeva S., Komori T., Stein G.S., Castilla L.H. Runx2 induces acute myeloid leukemia in cooperation with Cbfβ-SMMHC in mice. Blood 2009, 113:3323-3332.
11. Liu T.M., Lee E.H. Transcriptional regulatory cascades in Runx2-dependent bone development. Tissue Eng. Part B Rev 2013, 19:254-263.
12. Kayed H., Jiang X., Keleg S., Jesnowski R., Giese T., Berger M.R., et al. Regulation and functional role of the Runt-related transcription factor-2 in pancreatic cancer. Br. J. Cancer 2007, 97:1106-1115.
13. Chang C.H., Fan T.C., Yu J.C., Liao G.S., Lin Y.C., Shih A., et al. The prognostic significance of RUNX2 and miR-10a/10b and their inter-relationship in breast cancer. J. Transl. Med 2014, 12:257.
14. Wang Z.Q., Keita M., Bachvarova M., Gobeil S., Morin C., Plante M., et al. Inhibition of RUNX2 transcriptional activity blocks the proliferation, migration and invasion of epithelial ovarian carcinoma cells. PLoS ONE 2013, 8:74384.
15. Lim M., Zhong C., Yang S., Bell A.M., Cohen M.B., Roy-Burman P. Runx2 regulates survivin expression in prostate cancer cells. Lab. Invest 2009, 90:222-233.
16. Li H., Zhou R.J., Zhang G.Q., Xu J.P. Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study. Tumor Biol 2013, 34:1807-1812.
17. Boregowda R.K., Olabisi O.O., Abushahba W., Jeong B.S., Haenssen K.K., Chen W., et al. RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion. Cancer Lett 2014, 348:61-70.
18. Kurek K.C., Del Mare S., Salah Z., Abdeen S., Sadiq H., Lee S.H., et al. Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression. Cancer Res 2010, 70:5577-5586.
19. Blyth K., Terry A., Mackay N., Vaillant F., Bell M., Cameron E.R., et al. Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene 2001, 20:295-302.
20. Das K., Leong D.T., Gupta A., Shen L., Putti T., Stein G.S., et al. Positive association between nuclear Runx2 and estrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer. Eur. J. Cancer 2009, 45:2239-2248.
21. Onodera Y., Miki Y., Suzuki T., Takagi K., Akahira J., Sakyu T., et al. Runx2 in human breast carcinoma: its potential roles in cancer progression. Cancer Sci 2010, 101:2670-2675.
22. Barnes G.L., Javed A., Waller S.M., Kamal M.H., Hebert K.E., Hassan M.Q., et al. Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res 2003, 63:2631-2637.
23. Pratap J., Imbalzano K.M., Underwood J.M., Cohet N., Gokul K., Akech J., et al. Ectopic runx2 expression in mammary epithelial cells disrupts formation of normal acini structure: implications for breast cancer progression. Cancer Res 2009, 69:6807-6814.
24. Pratap J., Javed A., Languino L.R., van Wijnen A.J., Stein J.L., Stein G.S., et al. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol. Cell. Biol 2005, 25:8581-8591.
25. McDonald L., Ferrari N., Terry A., Bell M., Mohammed Z.M., Orange C., et al. RUNX2 correlates with subtype-specific breast cancer in a human tissue microarray, and ectopic expression of Runx2 perturbs differentiation in the mouse mammary gland. Dis. Mod. Mech 2014, 7:525-534.
26. Chua C.W., Chiu Y.T., Yuen H.F., Chan K.W., Man K., Wang X., et al. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform. Clin. Cancer Res 2009, 15:4322-4335.
27. Sancisi V., Borettini G., Maramotti S., Ragazzi M., Tamagnini I., Nicoli D., et al. Runx2 isoform I controls a panel of proinvasive genes driving aggressiveness of papillary thyroid carcinomas. J. Clin. Endocrinol. Metab 2012, 97:E2006-E2015.
28. Pande S., Browne G., Padmanabhan S., Zaidi S.K., Lian J.B., van Wijnen A.J., et al. Oncogenic cooperation between PI3K/Akt signaling and transcription factor Runx2 promotes the invasive properties of metastatic breast cancer cells. J. Cell. Physiol 2013, 228:1784-1792.
29. Tandon M., Chen Z., Pratap J. Runx2 activates PI3K/Akt signaling via mTORC2 regulation in invasive breast cancer cells. Breast Cancer Res 2014, 16:R16.
30. Mendoza-Villanueva D., Deng W., Lopez-Camacho C., Shore P. The Runx transcriptional co-activator, CBFbeta, is essential for invasion of breast cancer cells. Mol. Cancer 2009, 9:171.
31. Van der Deen M., Taipaleenmäki H., Zhang Y., Teplyuk N.M., Gupta A., Cinghu S., et al. MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma. J. Biol. Chem 2013, 288:21307-21319.
32. Zhang H., Pan Y., Zheng L., Choe C., Lindgren B., Jensen E.D., et al. FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res 2011, 71:3257-3267.
33. Huang Q., Jiang Z., Meng T., Yin H., Wang J., Wan W., et al. miR-30a inhibits osteolysis by targeting Runx2 in giant cell tumor of bone. Biochem. Biophys. Res. Commun 2014, 10.1016/j.bbrc.2014.09.076.
34. Endo T., Ohta K., Kobayashi T. Expression and function of Cbfa-1/Runx2 in thyroid papillary carcinoma cells. J. Clin. Endocrinol. Metab 2008, 93:2409-2412.
35. Ozaki T., Wu D., Sugimoto H., Nagase H., Nakagawara A. Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage. Cell Death Dis 2013, 4:e610.
36. Pratap J., Wixted J.J., Gaur T., Zaidi S.K., Dobson J., Gokul K.D., et al. Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res 2008, 68:7795-7802.
37. Blyth K., Vaillant F., Hanlon L., Mackay N., Bell M., Jenkins A., et al. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Res 2006, 66:2195-2201.
38. Heidari N., Miller A.V., Hicks M.A., Marking C.B., Harada H. Glucocorticoid-mediated BIM induction and apoptosis are regulated by Runx2 and c-Jun in leukemia cells. Cell Death Dis 2012, 3:e349.
39. Little G.H., Baniwal S.K., Adisetiyo H., Groshen S., Chimge N.O., Kim S.Y., et al. Differential effects of RUNX2 on the androgen receptor in prostate cancer: synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness. Cancer Res 2014, 74:2857-2868.
40. Gupta A., Cao W., Chellaiah M.A. Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad5/receptor activator of NF-κB ligand signaling axis. Mol. Cancer 2012, 11:66.
41. Tandon M., Gokul K., Ali S.A., Chen Z., Lian J., Stein G.S., et al. Runx2 mediates epigenetic silencing of the bone morphogenetic protein-3B (BMP-3B/GDF10) in lung cancer cells. Mol. Cancer 2012, 11:27.
42. Hsu Y.L., Huang M.S., Yang C.J., Hung J.Y., Wu L.Y., Kuo P.L. Lung tumor-associated osteoblast-derived bone morphogenetic protein-2 increased epithelial-to-mesenchymal transition of cancer by Runx2/Snail signaling pathway. J. Biol. Chem 2011, 286:37335-37346.
43. Yu W., Qiao Y., Tang X., Ma L., Wang Y., Zhang X., et al. Tumor suppressor long non-coding RNA, MT1DP is negatively regulated by YAP and Runx2 to inhibit FoxA1 in liver cancer cells. Cell. Signal 2014, 10.1016/j.cellsig.2014.09.011.
44. Niu D.F., Kondo T., Nakazawa T., Oishi N., Kawasaki T., Mochizuki K., et al. Transcription factor Runx2 is a regulator of epithelial-mesenchymal transition and invasion in thyroid carcinomas. Lab. Invest 2012, 92:1181-1190.
45. Sancisi V., Gandolfi G., Ragazzi M., Nicoli D., Tamagnini I., Piana S., et al. Cadherin 6 is a new RUNX2 target in TGF-β signaling pathway. PLoS ONE 2013, 8:e75489.
46. Zhang H.Y., Jin L., Stilling G.A., Ruebel K.H., Coonse K., Tanizaki Y., et al. RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumors. Endocrine 2009, 35:101-111.
47. Mendoza-Villanueva D., Zeef L., Shore P. Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ dependent expression of the Wnt antagonist, sclerostin. Breast Cancer Res 2011, 13:R106.
48. Wang D.C., Wang H.F., Yuan Z.N. Runx2 induces bone osteolysis by transcriptional suppression of TSSC1. Biochem. Biophys. Res. Commun 2013, 438:635-639.
49. Zhang S., Zhou X., Wang B., Zhang K., Liu S., Yue K., et al. Loss of VHL expression contributes to epithelial-mesenchymal transition in oral squamous cell carcinoma. Oral Oncol 2014, 50:809-817.
50. Zhang K.L., Zhou X., Han L., Chen L.Y., Chen L.C., Shi Z.D., et al. MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab. Mol. Cancer 2014, 13:63.
51. Leong D.T., Lim J., Goh X., Pratap J., Pereira B.P., Kwok H.S., et al. Cancer-related ectopic expression of the bone-related transcription factor RUNX2 in non-osseous metastatic tumor cells is linked to cell proliferation and motility. Breast Cancer Res 2010, 12:R89.
52. Zhang X., Akech J., Browne G., Russell S., Wixted J.J., Stein J.L., et al. Runx2-smad signaling impacts the progression of tumor-induced bone disease. Int. J. Cancer 2014, 10.1002/ijc.29094.
53. Olfa G., Christophe C., Philippe L., Romain S., Khaled H., Pierre H., et al. RUNX2 regulates the effects of TNFα on proliferation and apoptosis in SaOs-2 cells. Bone 2010, 46:901-910.
54. Zhang L., Zhou X., Yao X., Wu Y., Zhang Q., Zhang L. Oral tongue cancer patients show a better overall survival than base of tongue cancer patients. J. Cancer Res. Clin. Oncol 2012, 138:341-346.
55. Arena F. Clinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancer. Cancer Manag. Res 2014, 10.2147/CMAR.S56802.
56. Li Q., Song X.M., Ji Y.Y., Jiang H., Xu L.G. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro. Biochem. Biophys. Res. Commun 2013, 440:701-706.
57. Fu X., Creighton C.J., Biswal N.C., Kumar V., Shea M., Herrera S., et al. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res 2014, 16:430.
58. Mir R., Stanzani E., Martinez-Soler F., Villanueva A., Vidal A., Condom E., et al. YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression. Gynecol. Oncol 2014, 132:211-220.
59. Koike H., Nitta T., Sekine Y., Arai S., Furuya Y., Nomura M., et al. YM155 reverses rapamycin resistance in renal cancer by decreasing surviving. J. Cancer Res. Clin. Oncol 2014, 140:1705-1713.
60. Watanabe M., Sowa Y., Yogosawa M., Sakai T. Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells. Cancer Sci 2013, 104:687-693.
61. Jeong K.C., Kim K.T., Seo H.H., Shin S.P., Ahn K.O., Ji M.J., et al. Intravesical instillation of c-MYC inhibitor KSI-3716 suppresses orthotopic bladder tumor growth. J. Urol 2014, 191:510-518.
62. Ren Y., Zhou X., Qi Y., Li G., Mei M., Yao Z. PTEN activation sensitizes breast cancer to PI3-kinase inhibitor through the β-catenin signaling pathway. Oncol. Rep 2012, 28:943-948.
63. Ziros P.G., Georgakopoulos T., Habeos I., Basdra E.K., Papavassiliou A.G. Growth hormone attenuates the transcriptional activity of Runx2 by facilitating its physical association with Stat3β. J. Bone Miner. Res 2004, 19:1892-1904.
64. Zhou X., Ren Y., Liu A., Han L., Zhang K., Li S., et al. STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell carcinoma growth in vitro and in vivo. Oncol. Rep 2014, 31:2173-2180.
65. Zhou X., Zhang J., Jia Q., Ren Y., Wang Y., Shi L., et al. Reduction of miR-21 induces glioma cell apoptosis via activating caspase 9 and 3. Oncol. Rep 2010, 24:195.
66. Zhou X., Ren Y., Moore L., Mei M., You Y., Xu P., et al. Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab. Invest 2010, 90:144-155.
67. Islamian J.P., Mohammadi M., Baradaran B. Inhibition of human esophageal squamous cell carcinomas bytargeted silencing of tumor enhancer genes: an overview. Cancer Biol. Med 2014, 11:78-85.